Akt inhibitor MK‑2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine

Wang,Zhanshan; Luo,Guangtao; Qiu,Zhengjun

doi:10.3892/ol.2020.11300

Akt inhibitor MK‑2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine

Authors:
- Zhanshan Wang
- Guangtao Luo
- Zhengjun Qiu
View Affiliations

Affiliations: Department of General Surgery, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, P.R. China, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China
Published online on: January 14, 2020 https://doi.org/10.3892/ol.2020.11300
Pages: 1999-2004

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The PI3K/Akt pathway is an attractive therapeutic target in the treatment of pancreatic cancer, as it was demonstrated to be aberrantly regulated in pancreatic cancer cells. The present study aimed to investigate the therapeutic potential of the novel Akt inhibitor MK‑2206 in human pancreatic cancer cell lines. Pancreatic cancer cell survival following MK‑2206 treatment was assessed using the Cell Counting Kit‑8 (CCK‑8) assay, colony formation and determination of the apoptotic rate by flow cytometry following annexin‑V‑fluorescein isothiocyanate/propidium iodide staining. The effects of MK‑2206 alone or in combination with gemcitabine on pancreatic cell proliferation were assessed using the CCK‑8 assay. Western blotting was used to examine the effects of the two drugs on Akt protein expression. The results demonstrated that MK‑2206 inhibited the proliferation and induced apoptosis of the Mia PaCa‑2 and Panc‑1 pancreatic cancer cell lines. In addition, CCK‑8 cytotoxicity test showed that combined administration of MK‑2206 with gemcitabine enhanced the cytotoxic efficacy of gemcitabine. Furthermore, a low dose of MK‑2206 (1 µM) combined with gemcitabine was enough to inhibit Akt phosphorylation. Taken together, these results provided some insight into the underlying mechanism of the anticancer effects of MK‑2206 on pancreatic cancer cells.

View Figures

View References

1	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhang Q, Zeng L, Chen Y, Lian G, Qian C, Chen S, Li J and Huang K: Pancreatic cancer epidemiology, detection, and management. Gastroenterol Res Pract. 2016:8962321. 2016. View Article : Google Scholar
3	Zeng S, Pöttler M, Lan B, Grützmann R, Pilarsky C and Yang H: Chemoresistance in pancreatic cancer. Int J Mol Sci. 20:E45042019. View Article : Google Scholar : PubMed/NCBI
4	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
5	Manning BD and Toker A: AKT/PKB signaling: Navigating the network. Cell. 169:381–405. 2017. View Article : Google Scholar : PubMed/NCBI
6	Arlt A, Müerköster SS and Schäfer H: Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 332:346–358. 2013. View Article : Google Scholar : PubMed/NCBI
7	Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zhang XJ and Jia SS: Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways. Biomed Pharmacother. 83:1164–1174. 2016. View Article : Google Scholar : PubMed/NCBI
9	Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, et al: First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 29:4688–4701. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and Kotani H: MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lin YH, Chen BYH, Lai WT, Wu SF, Guh JH, Cheng AL and Hsu LC: The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 388:19–31. 2015. View Article : Google Scholar : PubMed/NCBI
12	Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB and Singh AP: An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4. J Biol Chem. 288:21197–21207. 2013. View Article : Google Scholar : PubMed/NCBI
13	Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R and Shokat KM: Inhibitor hijacking of Akt activation. Nat Chem Biol. 5:484–493. 2009. View Article : Google Scholar : PubMed/NCBI
14	Jin P, Wong CC, Mei S, He X, Qian Y and Sun L: MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. OncoTargets Ther. 9:4387–4396. 2016. View Article : Google Scholar
15	Li Z, Yan S, Attayan N, Ramalingam S and Thiele CJ: Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. Clin Cancer Res. 18:3603–3615. 2012. View Article : Google Scholar : PubMed/NCBI
16	Burke JF, Schlosser L, Harrison AD, Kunnimalaiyaan M and Chen H: MK-2206 causes growth suppression and reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. Ann Surg Oncol. 20:3862–3868. 2013. View Article : Google Scholar : PubMed/NCBI
17	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
18	Amrutkar M and Gladhaug IP: Pancreatic cancer chemoresistance to gemcitabine. Cancers. 9:157–180. 2017. View Article : Google Scholar
19	Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, et al: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol. 7:12014. View Article : Google Scholar : PubMed/NCBI
20	Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL and Gandara DR: Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who previously progressed on erlotinib. Clin Cancer Res. 21:4321–4326. 2015. View Article : Google Scholar : PubMed/NCBI
21	Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, Lim HJ, Hezel AF, Vaccaro GM and Blanke CD: Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S 1005). Cancer. 121:2193–2197. 2015. View Article : Google Scholar : PubMed/NCBI